Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2025)

Historic Receivables for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $74.3 million.

  • Tarsus Pharmaceuticals' Receivables rose 14530.1% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year increase of 14530.1%. This contributed to the annual value of $48.1 million for FY2024, which is 17130.52% up from last year.
  • Tarsus Pharmaceuticals' Receivables amounted to $74.3 million in Q3 2025, which was up 14530.1% from $60.2 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables peaked at $74.3 million during Q3 2025, and registered a low of $200000.0 during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Receivables had a median value of $20.2 million in 2021 and averaged $25.1 million.
  • Data for Tarsus Pharmaceuticals' Receivables shows a peak YoY increase of 169100.0% (in 2022) and a maximum YoY decrease of 9899.69% (in 2022) over the last 5 years.
  • Tarsus Pharmaceuticals' Receivables (Quarter) stood at $200000.0 in 2021, then soared by 1691.0% to $3.6 million in 2022, then soared by 394.53% to $17.7 million in 2023, then skyrocketed by 171.31% to $48.1 million in 2024, then skyrocketed by 54.68% to $74.3 million in 2025.
  • Its Receivables stands at $74.3 million for Q3 2025, versus $60.2 million for Q2 2025 and $64.2 million for Q1 2025.